EA8191 (INDICATE): Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence

About this Study

This study compares the addition of apalutamide, with or without targeted radiation therapy, to standard of care treatment versus standard of care treatment alone in patients with prostate cancer biochemical recurrence (a rise in the blood level of prostate-specific antigen [PSA] after treatment with surgery or radiation). 

Sponsor Protocol ID:EA8191
IRB Number:2020-0336
Actively Enrolling
Interventional
Phase 3
July 12, 2022
Eligibility Criteria
18 years old
Both Male and Female
Yes
No
No

Inclusion Criteria
  • Must have had radical prostatectomy for histopathologically-proven prostatic adenocarcinoma
  • Must have biochemical recurrence after radical prostatectomy, with rising PSA
  • Must have negative or equivocal for extrapelvic metastatic disease by imaging
  • Must be candidate for standard of care post-prostatectomy radiation therapy

Exclusion Criteria
  • Started androgen deprivation therapy for biochemical recurrence prior to baseline study PET/CT imaging
  • Enrolled in another therapeutic clinical trial
  • Diagnosed with other cancer within the last 2 years, other than superficial bladder cancer and skin basal cell carcinoma or cutaneous superficial squamous cell carcinoma that has not metastasized
  • History of seizures
  • History of inflammatory bowel disease
  • Prior radiation therapy

Categories Click category to view its trials.
Cancer
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Eulisa Goins-Freeman
Phone Number: 601-815-3936
Email: efreeman2@umc.edu
Principal Investigator:Henegan, John C, M.D.
How to participate in our Clinical Trials